Patents by Inventor Viktor Sergeevich TKACHEV

Viktor Sergeevich TKACHEV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetic information analysis platform oncobox
    Patent number: 11614434
    Abstract: The invention describes the method allowing for efficient predictive ranking of clinical efficiencies of the existing targeted medicinal products for individual patient with proliferative or oncology disease. The method makes it possible to use a wide range of experimental data received from the patients' pathological tissue samples and relevant control samples: information on gene mutations, transcription factor binding profile, protein (considering harmonization), mRNA (considering harmonization) and microRNA expression strength. The method also uses information on molecular targets of the medicinal products. This method can be automated to prevent potential errors associated with manual calculation and makes it possible to consider patient-specific changes in hundreds and thousands molecular pathways which include tens and hundreds of gene products. This method also considers the features and mode of action of various classes of target drugs.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 28, 2023
    Assignee: MICSWAY CORP.
    Inventors: Anton Alexandrovich Buzdin, Maksim Igorevich Sorokin, Viktor Sergeevich Tkachev, Daniil Mikhailovich Nikitin, Marianna Arsenovna Zolotovskaya, Andrey Vladimirovich Garazha, Nikolai Mikhailovich Borisov
  • Genetic Information Analysis Platform Oncobox
    Publication number: 20200292515
    Abstract: The invention describes the method allowing for efficient predictive ranking of clinical efficiencies of the existing targeted medicinal products for individual patient with proliferative or oncology disease. The method makes it possible to use a wide range of experimental data received from the patients' pathological tissue samples and relevant control samples: information on gene mutations, transcription factor binding profile, protein (considering harmonization), mRNA (considering harmonization) and microRNA expression strength. The method also uses information on molecular targets of the medicinal products. This method can be automated to prevent potential errors associated with manual calculation and makes it possible to consider patient-specific changes in hundreds and thousands molecular pathways which include tens and hundreds of gene products. This method also considers the features and mode of action of various classes of target drugs.
    Type: Application
    Filed: March 1, 2018
    Publication date: September 17, 2020
    Applicant: Obschestvo s ogranichennoi otvetstvennostyu "Oncobox"
    Inventors: Anton Alexandrovich BUZDIN, Maksim Igorevich SOROKIN, Viktor Sergeevich TKACHEV, Daniil Mikhailovich NIKITIN, Marianna Arsenovna ZOLOTOVSKAYA, Andrey Vladimirovich GARAZHA, Nikolai Mikhailovich BORISOV